{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:53:12Z","timestamp":1794001992377,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273411"],"award-info":[{"award-number":["82273411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974370"],"award-info":[{"award-number":["81974370"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32071229"],"award-info":[{"award-number":["32071229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gemcitabine resistance remains a major challenge in the treatment of gallbladder cancer (GBC). Here, we elucidate a novel mechanism underlying gemcitabine resistance in GBC, centered on a self-reinforcing mitophagy\/ROS\/SENP3\/Reptin loop. Gemcitabine-resistant GBC cells maintain significantly lower intracellular reactive oxygen species (ROS) levels than wild-type cells through enhanced mitophagy. This finding delineates a novel transcriptional mechanism that drives mitophagy under low ROS conditions. Mechanistically, this low ROS state decreases the protein abundance of the ROS sensor Sentrin\/SUMO-specific protease 3 (SENP3), thereby promoting SUMOylation of its substrate, RuvB-like AAA+ ATPase 2 (Reptin), at the K456 site. SUMOylated Reptin translocates to the nucleus, where it acts as a transcriptional activator to specifically upregulate PTEN-induced putative kinase 1 (PINK1), a key mitophagy regulator. Enhanced PINK1 expression further amplifies mitophagy, effectively scavenging ROS and perpetuating the low ROS state that drives resistance, thus sustaining the gemcitabine-resistant phenotype. Clinically, low SENP3 expression and high Reptin expression correlate with poor gemcitabine response and shorter overall survival in GBC patients. Targeting this pathway, the Reptin ATPase inhibitor CB-6644 effectively suppressed PINK1 transcription, inhibited mitophagy, increased ROS accumulation, and reversed gemcitabine resistance both in vitro and in vivo. These findings identify the mitophagy\/ROS\/SENP3\/Reptin loop as a core resistance mechanism in GBC, highlight SENP3 and Reptin as predictive biomarkers, and establish CB-6644 as a promising therapeutic agent to overcome gemcitabine resistance by disrupting this adaptive pathway.<\/jats:p>","DOI":"10.1038\/s41419-026-08598-0","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:02:17Z","timestamp":1788991337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SUMOylated Reptin maintains low intracellular ROS levels by activating mitophagy to drive gemcitabine resistance in gallbladder cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-2961","authenticated-orcid":false,"given":"Chuanxin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-2234","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-1338","authenticated-orcid":false,"given":"Yaodi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-9234","authenticated-orcid":false,"given":"Renhao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-8845","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"8598_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8598_CR2","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.3748\/wjg.v24.i45.5167","volume":"24","author":"Y Bai","year":"2018","unstructured":"Bai Y, Liu ZS, Xiong JP, Xu WY, Lin JZ, Long JY, et al. Nomogram to predict overall survival after gallbladder cancer resection in China. World J Gastroenterol. 2018;24:5167\u201378.","journal-title":"World J Gastroenterol"},{"key":"8598_CR3","first-page":"271","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271\u201389.","journal-title":"CA Cancer J Clin"},{"key":"8598_CR4","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109.","journal-title":"Clin Epidemiol"},{"key":"8598_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa JC, Garcia P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022;8:69.","journal-title":"Nat Rev Dis Primers"},{"key":"8598_CR6","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers, Version 2.2025."},{"key":"8598_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"8598_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103328","volume":"163","author":"AA Azizi","year":"2021","unstructured":"Azizi AA, Lamarca A, McNamara MG, Valle JW. Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163:103328.","journal-title":"Crit Rev Oncol Hematol"},{"key":"8598_CR9","first-page":"Cd011746","volume":"4","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4:Cd011746.","journal-title":"Cochrane Database Syst Rev"},{"key":"8598_CR10","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.cell.2023.04.026","volume":"186","author":"J Zhang","year":"2023","unstructured":"Zhang J, Simpson CM, Berner J, Chong HB, Fang J, Ordulu Z, et al. Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway. Cell. 2023;186:2361\u201379.e25.","journal-title":"Cell"},{"key":"8598_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009;8:579\u201391.","journal-title":"Nat Rev Drug Discov"},{"key":"8598_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2019.07.015","volume":"66","author":"DP Panigrahi","year":"2020","unstructured":"Panigrahi DP, Praharaj PP, Bhol CS, Mahapatra KK, Patra S, Behera BP, et al. The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. Semin Cancer Biol. 2020;66:45\u201358.","journal-title":"Semin Cancer Biol"},{"key":"8598_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-025-01727-w","volume":"18","author":"J Huang","year":"2025","unstructured":"Huang J, Pham VT, Fu S, Huang G, Liu YG, Zheng L. Mitophagy\u2019s impacts on cancer and neurodegenerative diseases: implications for future therapies. J Hematol Oncol. 2025;18:78.","journal-title":"J Hematol Oncol"},{"key":"8598_CR14","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1074\/jbc.M111.280156","volume":"287","author":"Y Kurihara","year":"2012","unstructured":"Kurihara Y, Kanki T, Aoki Y, Hirota Y, Saigusa T, Uchiumi T, et al. Mitophagy plays an essential role in reducing mitochondrial production of reactive oxygen species and mutation of mitochondrial DNA by maintaining mitochondrial quantity and quality in yeast. J Biol Chem. 2012;287:3265\u201372.","journal-title":"J Biol Chem"},{"key":"8598_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/ars.2020.8058","volume":"34","author":"JH Schofield","year":"2021","unstructured":"Schofield JH, Schafer ZT. Mitochondrial Reactive Oxygen Species and Mitophagy: A Complex and Nuanced Relationship. Antioxid Redox Signal. 2021;34:517\u201330.","journal-title":"Antioxid Redox Signal"},{"key":"8598_CR16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.7150\/thno.79876","volume":"13","author":"Y Lu","year":"2023","unstructured":"Lu Y, Li Z, Zhang S, Zhang T, Liu Y, Zhang L. Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation. Theranostics. 2023;13:736\u201366.","journal-title":"Theranostics"},{"key":"8598_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41392-023-01503-7","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, Long H, Hou L, Feng B, Ma Z, Wu Y, et al. The mitophagy pathway and its implications in human diseases. Signal Transduct Target Ther. 2023;8:304.","journal-title":"Signal Transduct Target Ther"},{"key":"8598_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc.2016.143","volume":"17","author":"JS Seeler","year":"2017","unstructured":"Seeler JS, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer. 2017;17:184\u201397.","journal-title":"Nat Rev Cancer"},{"key":"8598_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13238-015-0216-7","volume":"7","author":"M Wang","year":"2016","unstructured":"Wang M, Sang J, Ren Y, Liu K, Liu X, Zhang J, et al. SENP3 regulates the global protein turnover and the Sp1 level via antagonizing SUMO2\/3-targeted ubiquitination and degradation. Protein Cell. 2016;7:63\u201377.","journal-title":"Protein Cell"},{"key":"8598_CR20","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1038\/emboj.2009.210","volume":"28","author":"C Huang","year":"2009","unstructured":"Huang C, Han Y, Wang Y, Sun X, Yan S, Yeh ET, et al. SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. Embo j. 2009;28:2748\u201362.","journal-title":"Embo j"},{"key":"8598_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.molcel.2020.12.024","volume":"81","author":"Z Hu","year":"2021","unstructured":"Hu Z, Teng XL, Zhang T, Yu X, Ding R, Yi J, et al. SENP3 senses oxidative stress to facilitate STING-dependent dendritic cell antitumor function. Mol Cell. 2021;81:940\u201352.e5.","journal-title":"Mol Cell"},{"key":"8598_CR22","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.1158\/0008-5472.CAN-08-0547","volume":"68","author":"O Huber","year":"2008","unstructured":"Huber O, Menard L, Haurie V, Nicou A, Taras D, Rosenbaum J. Pontin and reptin, two related ATPases with multiple roles in cancer. Cancer Res. 2008;68:6873\u20136.","journal-title":"Cancer Res"},{"key":"8598_CR23","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1152\/physrev.00025.2019","volume":"100","author":"HM Chang","year":"2020","unstructured":"Chang HM, Yeh ETH. SUMO: From Bench to Bedside. Physiol Rev. 2020;100:1599\u2013619.","journal-title":"Physiol Rev"},{"key":"8598_CR24","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1016\/j.immuni.2025.07.024","volume":"58","author":"Z Song","year":"2025","unstructured":"Song Z, Xie X, Chen Y, Zhang B, Li X, Yang Y, et al. Innate immune sensing of Z-nucleic acids by ZBP1-RIPK1 axis drives neuroinflammation in Alzheimer\u2019s disease. Immunity. 2025;58:2574\u201392.e9.","journal-title":"Immunity"},{"key":"8598_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.molcel.2008.02.005","volume":"29","author":"A Tanaka","year":"2008","unstructured":"Tanaka A, Youle RJ. A chemical inhibitor of DRP1 uncouples mitochondrial fission and apoptosis. Mol Cell. 2008;29:409\u201310.","journal-title":"Mol Cell"},{"key":"8598_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1021\/acschembio.8b00904","volume":"14","author":"VA Assimon","year":"2019","unstructured":"Assimon VA, Tang Y, Vargas JD, Lee GJ, Wu ZY, Lou K, et al. CB-6644 Is a Selective Inhibitor of the RUVBL1\/2 Complex with Anticancer Activity. ACS Chem Biol. 2019;14:236\u201344.","journal-title":"ACS Chem Biol"},{"key":"8598_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40880-018-0318-8","volume":"38","author":"M Zhan","year":"2018","unstructured":"Zhan M, Yang RM, Wang H, He M, Chen W, Xu SW, et al. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients. Cancer Commun (Lond). 2018;38:48.","journal-title":"Cancer Commun (Lond)"},{"key":"8598_CR28","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17:v7\u201312.","journal-title":"Ann Oncol"},{"key":"8598_CR29","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931\u201347.","journal-title":"Nat Rev Drug Discov"},{"key":"8598_CR30","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1111\/jcmm.13126","volume":"21","author":"H Zhao","year":"2017","unstructured":"Zhao H, Duan Q, Zhang Z, Li H, Wu H, Shen Q, et al. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. J Cell Mol Med. 2017;21:2055\u201367.","journal-title":"J Cell Mol Med"},{"key":"8598_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","volume":"22","author":"EC Cheung","year":"2022","unstructured":"Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer. 2022;22:280\u201397.","journal-title":"Nat Rev Cancer"},{"key":"8598_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","volume":"24","author":"J Debnath","year":"2023","unstructured":"Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24:560\u201375.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8598_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-023-02638-9","volume":"42","author":"Y Sun","year":"2023","unstructured":"Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T, et al. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J Exp Clin Cancer Res. 2023;42:65.","journal-title":"J Exp Clin Cancer Res"},{"key":"8598_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06164-6","volume":"14","author":"N Mu","year":"2023","unstructured":"Mu N, Wang Y, Li X, Du Z, Wu Y, Su M, et al. Crotonylated BEX2 interacts with NDP52 and enhances mitophagy to modulate chemotherapeutic agent-induced apoptosis in non-small-cell lung cancer cells. Cell Death Dis. 2023;14:645.","journal-title":"Cell Death Dis"},{"key":"8598_CR35","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1016\/j.celrep.2017.08.087","volume":"20","author":"E Villa","year":"2017","unstructured":"Villa E, Pro\u00efcs E, Rubio-Pati\u00f1o C, Obba S, Zunino B, Bossowski JP, et al. Parkin-Independent Mitophagy Controls Chemotherapeutic Response in Cancer Cells. Cell Rep. 2017;20:2846\u201359.","journal-title":"Cell Rep"},{"key":"8598_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05711-5","volume":"14","author":"C Qin","year":"2023","unstructured":"Qin C, Wang Y, Zhao B, Li Z, Li T, Yang X, et al. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. Cell Death Dis. 2023;14:191.","journal-title":"Cell Death Dis"},{"key":"8598_CR37","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-17-2288","volume":"78","author":"B Wei","year":"2018","unstructured":"Wei B, Huang C, Liu B, Wang Y, Xia N, Fan Q, et al. Mitotic Phosphorylation of SENP3 Regulates DeSUMOylation of Chromosome-Associated Proteins and Chromosome Stability. Cancer Res. 2018;78:2171\u20138.","journal-title":"Cancer Res"},{"key":"8598_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05676-6","volume":"9","author":"X Yu","year":"2018","unstructured":"Yu X, Lao Y, Teng XL, Li S, Zhou Y, Wang F, et al. SENP3 maintains the stability and function of regulatory T cells via BACH2 deSUMOylation. Nat Commun. 2018;9:3157.","journal-title":"Nat Commun"},{"key":"8598_CR39","doi-asserted-by":"publisher","first-page":"1701637","DOI":"10.1183\/13993003.01637-2017","volume":"52","author":"JH Mikesch","year":"2018","unstructured":"Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, et al. Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. Eur Respir J. 2018;52:1701637.","journal-title":"Eur Respir J"},{"key":"8598_CR40","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1136\/gutjnl-2017-314208","volume":"67","author":"J Javary","year":"2018","unstructured":"Javary J, Allain-Courtois N, Saucisse N, Costet P, Heraud C, Benhamed F, et al. Liver Reptin\/RUVBL2 controls glucose and lipid metabolism with opposite actions on mTORC1 and mTORC2 signalling. Gut. 2018;67:2192\u2013203.","journal-title":"Gut"},{"key":"8598_CR41","doi-asserted-by":"crossref","unstructured":"Rousseau B, M\u00e9nard L, Haurie V, Taras D, Blanc JF, Moreau-Gaudry F, et al. Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology. 2007;46:1108\u201318.","DOI":"10.1002\/hep.21770"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08598-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:02:19Z","timestamp":1788991339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08598-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8598"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08598-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was performed in accordance with the Declaration of Helsinki, and received approval from the Ethics Committee of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (No. 2020-243). Written informed consent was obtained from all subjects involved in the study. Animal procedures were conducted in accordance with the National Institutes of Health Guidelines and approved by the Institutional Animal Care and Use Committee of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (No. 2024-0273).","order":2,"name":"Ethics","label":"Ethics Statement","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"394"}}